OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Each product in OncoGenex's oncology pipeline has a distinct mechanism of action and represents a unique opportunity for cancer drug development.

OGX-011, our lead product candidate, has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex is collaborating with Teva Pharmaceuticals on a global Phase III clinical program with two Phase III clinical trials expected to be initiated in 2010: a Phase III Study for Second-line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC) and a Phase III Study in First-Line Chemotherapy for Metastatic CRPC. An additional Phase III Study in First-Line Treatment of Advanced, Unresectable Non-Smalll Cell Lung Cancer (NSCLC) is intended to be initiated by early 2011.

OGX-011 is presently being developed to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising pre-clinical and Phase II clinical results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.